July 23, 2024 10:56 AM EDTUpdated 02:08 PM
R&D

Cel­lec­tar to seek ap­proval for ra­dioac­tive io­dine-based ther­a­py in rare blood can­cer

Lei Lei Wu

News Reporter

Cel­lec­tar Bio­sciences re­port­ed Tues­day that 80% of pa­tients with a rare blood can­cer eval­u­at­ed in a piv­otal study re­spond­ed to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times